Zhaoke Ophthalmology's (HKG:6622) phase 3 trial of its TAB014 treatment for wet (neovascular) age-related macular degeneration met primary and key secondary endpoints, according to a Thursday filing with the Hong Kong Exchange.
The trial enrolled 488 patients across 57 centers and assessed changes from baseline in best corrected visual acuity at 52 weeks for patients treated with TAB014.
Shares jumped 7% during Thursday's trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。